NYSEAMERICAN:ARMP - Armata Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Armata Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.22 +2.43 (+87.10 %) (As of 01/28/2020 01:21 PM ET) Add Compare Today's Range$3.30Now: $5.22▼$6.9150-Day Range N/A52-Week Range$2.45Now: $5.22▼$6.23Volume170,479 shsAverage Volume22,665 shsMarket Capitalization$51.86 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorHealth Technology Current SymbolNYSEAMERICAN:ARMP Previous Symbol CUSIPN/A CIKN/A WebN/A Phone(310) 655-2928Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares9,934,000Market Cap$51.86 million Next Earnings Date3/23/2020 (Estimated) OptionableNot Optionable Receive ARMP News and Ratings via Email Sign-up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter. AMEX:ARMP Rates by TradingView Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Frequently Asked Questions What is Armata Pharmaceuticals' stock symbol? Armata Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ARMP." How were Armata Pharmaceuticals' earnings last quarter? Armata Pharmaceuticals Inc (NYSEAMERICAN:ARMP) issued its earnings results on Tuesday, November, 12th. The company reported ($0.73) EPS for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.34. View Armata Pharmaceuticals' Earnings History. When is Armata Pharmaceuticals' next earnings date? Armata Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Armata Pharmaceuticals. What price target have analysts set for ARMP? 2 brokers have issued twelve-month target prices for Armata Pharmaceuticals' shares. Their forecasts range from $9.00 to $9.50. On average, they anticipate Armata Pharmaceuticals' share price to reach $9.25 in the next year. This suggests a possible upside of 75.9% from the stock's current price. View Analyst Price Targets for Armata Pharmaceuticals. What is the consensus analysts' recommendation for Armata Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Armata Pharmaceuticals. What are Wall Street analysts saying about Armata Pharmaceuticals stock? Here are some recent quotes from research analysts about Armata Pharmaceuticals stock: 1. According to Zacks Investment Research, "Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. " (1/14/2020) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy and $7 price target. The sole contributor to our valuation, at this point is AB-SA01, with a projected 15% chance of success with $415 million in peak sales off of a 2024 launch. Overall, we believe that our projected chance of success could be considered conservative based on the efficacy and safety profile, to date, in very sick patients, and continues to highlight the valuation disconnect, in our belief. We do not include projections for the P. aeruginosa program, and would look to reevaluate based on visibility on the path forward." (8/15/2019) Has Armata Pharmaceuticals been receiving favorable news coverage? Media coverage about ARMP stock has trended somewhat positive recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Armata Pharmaceuticals earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the near term. View News Stories for Armata Pharmaceuticals. Are investors shorting Armata Pharmaceuticals? Armata Pharmaceuticals saw a increase in short interest in January. As of January 15th, there was short interest totalling 112,700 shares, an increase of 9.8% from the December 31st total of 102,600 shares. Based on an average trading volume of 14,600 shares, the short-interest ratio is presently 7.7 days. Approximately 2.9% of the company's shares are sold short. View Armata Pharmaceuticals' Current Options Chain. Who are some of Armata Pharmaceuticals' key competitors? Some companies that are related to Armata Pharmaceuticals include Faron Pharmaceuticals Oy (FARN), Oxford Biodynamics (OBD), Sirona Biochem (SBM), Ampliphi Biosciences (APHB), Equillium (EQ), Orgenesis (ORGS), Botanix Pharmaceuticals (BOT), Acasti Pharma (ACST), Orthocell (OCC), Medlab Clinical (MDC), Pediapharm (PDP), 4d Pharma (DDDD), Promis Neurosciences (PMN), Verona Pharma (VRP) and Protalix Biotherapeutics (PLX). What other stocks do shareholders of Armata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include vTv Therapeutics (VTVT), Vaxart (VXRT), Agile Therapeutics (AGRX), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Adamas Pharmaceuticals (ADMS), Aytu Bioscience (AYTU), Verizon Communications (VZ), Anavex Life Sciences (AVXL) and Cellectar Biosciences (CLRB). Who are Armata Pharmaceuticals' key executives? Armata Pharmaceuticals' management team includes the folowing people: Todd R. Patrick, Chief Executive Officer & DirectorBrian C. Varnum, President & Chief Development OfficerDuane A. Morris, Vice President-OperationsSteven Robert Martin, Chief Financial Officer & Head-Media Contacts How do I buy shares of Armata Pharmaceuticals? Shares of ARMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Armata Pharmaceuticals' stock price today? One share of ARMP stock can currently be purchased for approximately $5.26. How big of a company is Armata Pharmaceuticals? Armata Pharmaceuticals has a market capitalization of $52.25 million. View Additional Information About Armata Pharmaceuticals. How can I contact Armata Pharmaceuticals? The company can be reached via phone at (310) 655-2928. MarketBeat Community Rating for Armata Pharmaceuticals (NYSEAMERICAN ARMP)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 20 (Vote Outperform)Underperform Votes: 17 (Vote Underperform)Total Votes: 37MarketBeat's community ratings are surveys of what our community members think about Armata Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARMP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/28/2020 by MarketBeat.com StaffFeatured Article: What is Depreciation?
